French version of the Schizophrenia Proneness Instrument for children and adolescents (SPI-CY)
French Validation of Schizophrenia Proneness Instrument- Child Youth
This project will test the French SPI-CY to see if it reliably identifies French-speaking adolescents (ages 12–17) who are at high risk for developing psychosis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 52 (estimated) |
| Ages | 12 Years to 17 Years |
| Sex | All |
| Sponsor | Centre Psychothérapique de Nancy Academic / other |
| Locations | 3 sites (Lille and 2 other locations) |
| Trial ID | NCT06649552 on ClinicalTrials.gov |
What this trial studies
This multicenter work enrolls French-speaking adolescents aged 12 to 17 who are already identified as being at clinical high risk for psychosis and administers the SPI-CY interview, with audio recording of sessions. Investigators will examine the instrument's reliability and how well its scores agree with existing clinical measures such as CAARMS and clinical judgment. The goal is to produce psychometric data (e.g., internal consistency, interrater reliability, and predictive indicators) for the French version. The project is conducted at three French centers (Nancy, Lille, Saint-Egrève) using standard psychiatric diagnostic interview procedures.
Who should consider this trial
Good fit: Ideal candidates are French-speaking adolescents aged 12 to 17 years 11 months who are followed at one of the three participating centers for suspected clinical high risk of psychosis and who (and whose parent) consent to audio recording of the interview.
Not a fit: Patients outside the 12–17 age range, non–French speakers, those unwilling to be audio-recorded, pregnant individuals, or those deprived of liberty are unlikely to be eligible or to benefit from this protocol.
Why it matters
Potential benefit: If successful, a validated French SPI-CY could improve early detection of prodromal symptoms in adolescents, enabling earlier support and interventions to delay or prevent a first psychotic episode.
How similar studies have performed: The basic symptoms approach and the adult SPI-A have prior international validation and clinical use, while translations and validations of the SPI-CY are less widespread, making this French validation a necessary extension of earlier work.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria : * Patients (men or women) followed at one of the 3 following structures in France : CLIP-Ado Nancy, CH Alpes-Isère, CHRU Lille for a suspected mental state at risk of developing psychosis, as determined by the CAARMS scale and/or the SPI-CY scale. * Age between 12 and 17 years and 11 months * Affiliation with a social security scheme or beneficiary of such a scheme. * Native language: French. * Adolescents who have been informed of the study, have received the study information note and have not objected to participating in the study * At least one of the holders of parental authority having been informed of the study, having received the relevant information note and not having objected to the adolescent participation * Consent to audio recording of the SPI-CY scale administration: for the adolescent and at least one parent. Exclusion Criteria: * Pregnant woman, parturient or nursing mother * Person deprived of liberty by judicial or administrative decision * Person in a life-threatening emergency * Impairment of the subject that makes it difficult, if not impossible, to participate in the trial or to understand the information provided. * Abuse or dependence on any substance according to DSM V criteria, excluding cannabis
Where this trial is running
Lille and 2 other locations
- CHRU Lille — Lille, France (Not_yet_recruiting)
- Centre Psychothérapique de Nancy — Nancy, France (Recruiting)
- CH Alpes-Isère — Saint-Egrève, France (Recruiting)
Study contacts
- Principal investigator: Florent BERNARDIN — Centre Psychothérapique de Nancy (CPN)
- Study coordinator: Florent BERNARDIN
- Email: florent.bernardin@cpn-laxou.com
- Phone: 0033 3 83 26 08 63
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.